7 active not recruiting. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 7 |
Follow Refractory Ependymoma: new trials by email Literature Review of Refractory Ependymoma trials Research Report on Refractory Ependymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-28 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-06-17 |
Ependymoma (7) · Glioma (7) · Hepatoblastoma (7) · Histiocytosis, Langerhans-Cell (7) · Lymphoma, Non-Hodgkin (7) · Medulloblastoma (7) · Neuroblastoma (7) · Neuroectodermal Tumors, Primitive, Peripheral (7) · Rhabdoid Tumor (7) · Wilms Tumor (7) · Osteosarcoma (6) · Rhabdomyosarcoma (6) · Sarcoma (6) · Sarcoma, Ewing (4) · Central Nervous System Neoplasms (3)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genetic Diseases, Inborn (7) · Hemic and Lymphatic Diseases (7) · Histiocytosis (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Kidney Diseases (7) · Kidney Neoplasms (7) · Lung Diseases (7) · Lung Diseases, Interstitial (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Male Urogenital Diseases (7)
Magnetic Resonance Spectroscopy (4) · Nuclear Medicine Department, Hospital (4) · Phantoms, Imaging (4) · X-Rays (4) · Biopsy (3) · Specimen Handling (3) · Pharmacogenomic Variants (1) · ensartinib (1) · erdafitinib (1) · ivosidenib (1) · larotrectinib (1) · selpercatinib (1) · tipifarnib (1) · ulixertinib (1)
National Cancer Institute (NCI) (7)
Puerto Rico (7) · United States (7) · Australia (3) · Canada (1)
Alice Lee (1) · Andrea T Franson (1) · Christine A Pratilas (1) · Elizabeth D Alva (1) · Katherine A Janeway (1) · Kieuhoa T Vo (1) · Meredith S Irwin (1)
PMID 31401903, PMID 34486544, PMID 38935895, PMID 42853672, PMID 42867148
U10CA180886 (7), UM1CA081457 (1)